Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 29;12:675678. doi: 10.3389/fimmu.2021.675678

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Della-Torre, Lanzillotta, Campochiaro, Cavalli, De Luca, Tomelleri, Boffini, De Lorenzo, Ruggeri, Rovere-Querini, Castagna, Landoni, Tresoldi, Ciceri, Zangrillo and Dagna

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cumulative incidence of long-term survival of patients treated with biologic drugs compared to patients treated with standard of care (PaO2/FiO2 ratio ≥ mmHg). Kaplan-Meier curves showing the cumulative incidence of overall survival up to 186 days of patients presenting with a PaO2/FiO2 ratio ≥ mmHg and treated with biologic drugs (A), anakinra (B), sarilumab (C), and tocilizumab (D), compared to standard of care. Time to death is expressed in days from the day of enrolment. A, anakinra; B, biologic drugs; C, comparators treated with standard of care; S, sarilumab; T, tocilizumab; HR, hazard ratio; CI, confidence interval. Statistically significant p value < 0.05.